glp 1 co to jest The GLP-1 revolution: What UAB researchers are discovering about how these drugs work GLP-1 Drugs from the Gray
Description
2024 doi: 10.1056/NEJMoa2410819
Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)
Among the most promising developments is Amycretin, a dual-acting GLP-1 and amylin receptor agonist developed by Novo Nordisk
While randomized prevention trials are still needed, the consistency and biological coherence of current data support cautious optimism
Similar effectiveness has been shown by other medications including one recent study published in JAMA which showed a 5 to 20% weight loss
